• HOME
  •  > 
  • 薬学
  •  > 
  • 雑誌
  •  >  医学と薬学　79/10　2022年10月号

医学と薬学　79/10　2022年10月号

出版社： 自然科学社
発行日： 2022-09-27
分野： 薬学  >  雑誌
ISSN： 03893898
雑誌名：
特集： 動脈硬化性疾患についての最新の話題
電子書籍版： 2022-09-27 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

1,540 円(税込)

購入する

目次

  • 特集　動脈硬化性疾患についての最新の話題
    　　　―「動脈硬化性疾患予防ガイドライン2022年版」を踏まえて

    序文
    動脈硬化性疾患の包括的リスク評価
    動脈硬化性疾患予防のための生活習慣指導
    動脈硬化性疾患予防ガイドラインの概要
    動脈硬化症予防のための脂質管理
    　―薬物療法
    家族性高コレステロール血症に対する包括的リスク管理
    脂質異常症に対する新規薬剤の開発状況

    臨床試験
    　トルバプタンOD錠15mg「トーワ」の日本人健康成人男性における生物学的同等性試験
    　エスシタロプラムOD錠10mg「トーワ」の日本人健康成人男性における生物学的同等性試験

    薬理・薬剤
    　独自の形状を有するエスシタロプラム錠「ニプロ」の品質評価
    　各種病原ウイルス（SARS-CoV-2等）に対する医薬品類および雑貨品の有効性判定

    研究
    　コナヒョウヒダニ抽出物投与によるマウス喘息モデルの有用性
    　Investigation into Performance of 2 -μm Diameter Microfiber Cloth
    　　in Removing Feline Enteric Coronavirus（FECoV）

    Diagnosis
    　唾液検体に対する銀増幅イムノクロマトグラフィーを用いた
    　　SARS-CoV-2抗原検出システムの臨床性能評価
    　COVID-19確定患者における肺炎球菌の重複感染に関する研究
    　　―尿中肺炎球菌抗原キット「クイックチェイサー®肺炎球菌II」の有用性―
    　ルミパルス®L2400を用いたメトトレキサート定量試薬
    　 「ルミパルスプレスト®メトトレキサート」の基礎性能評価

    Cosmetic
    「シズカホワイトバーム」の使用が加齢肌に及ぼす影響
    　　―抗シワ，洗浄，美白　―ヒト臨床試験―

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

【特集 動脈硬化性疾患についての最新の話題 - 「動脈硬化性疾患予防ガイドライン2022年版」を踏まえて】

P.1256 掲載の参考文献
1) 日本動脈硬化学会 編 : 動脈硬化性疾患予防ガイドライン 2022年版, 2022.
 
2) 日本動脈硬化学会 編 : 動脈硬化性疾患予防ガイドライン 2017年版, 2017.
 
3) Grundy SM, Stone NJ, Bailey AL, et al : 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol : Executive Summary : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 139 : e1046-e1081, 2019.
 
4) Mach F, Baigent C, Catapano AL, et al : 2019 ESC/EAS Guidelines for the management of dyslipidaemias : lipid modification to reduce cardiovascular risk. Eur Heart J 41 : 111-188, 2020.
PubMed
5) Nakai M, Watanabe M, Kokubo Y, et al : Development of a Cardiovascular Disease Risk Prediction Model Using the Suita Study, a Population-Based Prospective Cohort Study in Japan. J Atheroscler Thromb 27 : 1160-1175, 2020.
PubMed
6) Honda T, Chen S, Hata J, et al : Development and Validation of a Risk Prediction Model for Atherosclerotic Cardiovascular Disease in Japanese Adults : The Hisayama Study. J Atheroscler Thromb 29 : 345-361, 2022.
PubMed
7) Itoh H, Komuro I, Takeuchi M, et al : Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy : Report of a Randomized Study. Diabetes Care 41 : 1275-1284, 2018.
PubMed
8) Hosomi N, Nagai Y, Kohriyama T, et al : The Japan Statin Treatment Against Recurrent Stroke (J-STARS) : A Multicenter, Randomized, Open-label, Parallel-group Study. EBioMedicine 2 : 1071-1078, 2018.
 
9) Taguchi I, Iimuro S, Iwata H, et al : High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD) : A Randomized Superiority Trial. Circulation 137 : 1997-2009, 2018.
PubMed
10) Nishimura K, Okamura T, Watanabe M, et al : Predicting coronary heart disease using risk factor categories for a Japanese urban population, and comparison with the Framingham risk score : the Suita study. J Atheroscler Thromb 21 : 784-798, 2014.
PubMed
11) Imamura T, Doi Y, Arima H, et al : LDL cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population : the Hisayama study. Stroke 40 : 382-388, 2009.
 
12) Imai Y, Mizuno Tanaka S, Satoh M, et al : Prediction of Lifetime Risk of Cardiovascular Disease Deaths Stratified by Sex in the Japanese Population. J Am Heart Assoc 10 : e021753, 2021.
PubMed
P.1266 掲載の参考文献
1) 日本動脈硬化学会 編 : 動脈硬化性疾患予防ガイドライン 2022年版, 2022.
 
2) Cui R, Iso H, Toyoshima H, et al : Body mass index and mortality from cardiovascular disease among Japanese men and women. The JACC study. Stroke 36 : 1377-1382, 2005.
PubMed
3) Seidelmann SB, Claggett B, Cheng S, et al : Dietary carbohydrate intake and mortality : a prospective cohort study and meta-analysis. Lancet Public Health 3 : e419-e428, 2018.
PubMed
4) Abdelhamid AS, Brown TJ, Brainard JS, et al : Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 3 : CD003177, 2020.
PubMed
5) Hooper L, Martin N, Jimoh OF, et al : Reduction in saturated fat intake for cardiovascular disease. Cochrane Database Syst Rev 8 : CD011737, 2020.
 
6) Farvid MS, Ding M, Pan A, et al : Dietary linoleic acid and risk of coronary heart disease : a systematic review and meta-analysis of prospective cohort studies. Circulation 130 : 1568-1578, 2014.
PubMed
7) Schwingshackl L, Strasser B, Hoffmann G : Effects of monounsaturated fatty acids on cardiovascular risk factors : a systematic review and meta-analysis. Ann Nutr Metab 59 : 176-186, 2011.
PubMed
8) Zhong VW, Van Horn L, Cornelis MC, et al : Associations of dietary cholesterol or egg consumption with incident cardiovascular disease and mortality. JAMA 321 : 1081-1095, 2019.
PubMed
9) Berger S, Raman G, Vishwanathan R, et al : Dietary cholesterol and cardiovascular disease : a systematic review and meta-analysis. Am J Clin Nutr 102 : 276-294, 2015.
PubMed
10) Johnson C, Greenland P : Effects of exercise, dietary cholesterol, and dietary fat on blood lipids. Arch Intern Med 150 : 137-141, 1990.
PubMed
11) Eshak ES, Iso H, Date C, et al : Dietary fiber intake is associated with reduced risk of mortality from cardiovascular disease among Japanese men and women. J Nutr 140 : 1445-1453, 2010.
PubMed
12) Reynolds A, Mann J, Cummings J, et al : Carbohydrate quality and human health : a series of systematic reviews and meta-analyses. Lancet 393 : 434-445, 2019.
 
13) 日本動脈硬化学会 学術委員会栄養部会 編 : The Japan Diet. https://www.j-athero.org/jp/general/9_japandiet/
 
P.1273 掲載の参考文献
1) 日本動脈硬化学会 編 : 動脈硬化性疾患予防ガイドライン 2022年版, 2022.
 
2) Noda H, Iso H, Saito I, et al : The impact of the metabolic syndrome and its components on the incidence of ischemic heart disease and stroke : the Japan public health center-based study. Hypertens Res 32 : 289-298, 2009.
PubMed
3) Iso H, Imano H, Yamagishi K, et al : Fasting and non-fasting triglycerides and risk of ischemic cardiovascular disease in Japanese men and women : the Circulatory Risk in Communities Study (CIRCS). Atherosclerosis 237 : 361-368, 2014.
PubMed
4) Higashiyama A, Wakabayashi I, Okamura T, et al : The Risk of Fasting Triglycerides and its Related Indices for Ischemic Cardiovascular Diseases in Japanese Community Dwellers : the Suita Study. J Atheroscler Thromb 28 : 1275-1288, 2021.
PubMed
5) Iso H, Naito Y, Sato S, et al : Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol 153 : 490-499, 2001.
PubMed
6) Kubo M, Hata J, Doi Y, et al : Secular trends in the incidence of and risk factors for ischemic stroke and its subtypes in Japanese population. Circulation 118 : 2672-2678, 2008.
PubMed
7) 国循脳卒中データバンク編集委員会 編 : 脳卒中治療データバンク 2021. 中山書店, 東京, 2021.
 
8) Honda T, Chen S, Hata J, et al : Development and Validation of a Risk Prediction Model for Atherosclerotic Cardiovascular Disease in Japanese Adults : The Hisayama Study. J Atheroscler Thromb 29 : 345-361, 2022.
PubMed
9) Kadowaki S, Okamura T, Hozawa A, et al : Relationship of elevated casual blood glucose level with coronary heart disease, cardiovascular disease and all-cause mortality in a representative sample of the Japanese population. NIPPON DATA80. Diabetologia 51 : 575-582, 2008.
 
10) Colhoun HM, Betteridge DJ, Durrington PN, et al : Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS) : multicentre randomised placebo-controlled trial. Lancet 364 : 685-696, 2004.
PubMed
11) Gaede P, Lund-Andersen H, Parving HH, et al : Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358 : 580-591, 2008
PubMed
12) Tada H, Hori M, Matsuki K, et al : Achilles Tendon Thickness Assessed by X-ray Predicting a Pathogenic Mutation in Familial Hypercholesterolemia Gene. J Atheroscler Thromb 29 : 816-824, 2022
 
P.1282 掲載の参考文献
1) Baigent C, Keech A, Kearney PM, et al : Efficacy and safety of cholesterol-lowering treatment : prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 : 1267-1278, 2005.
PubMed
2) Baigent C, Blackwell L, Emberson J, et al : Efficacy and safety of more intensive lowering of LDL cholesterol : a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376 : 1670-1681. 2010.
PubMed
3) Mihaylova B, Emberson J, Blackwell L, et al : The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease : meta-analysis of individual data from 27 randomised trials. Lancet 380 : 581-590, 2012.
PubMed
4) Fulcher J, O'Connell R, Voysey M, et al : Efficacy and safety of LDL-lowering therapy among men and women : meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 385 : 1397-1405, 2015.
PubMed
5) Itakura H, Kita T, Mabuchi H, et al : Relationship between coronary events and serum cholesterol during 10 years of low-dose simvastatin therapy : long-term efficacy and safety in Japanese patients with hypercholesterolemia in the Japan Lipid Intervention Trial (J-LIT) Extension 10 Study, a prospective large-scale observational cohort study. Circ J 72 1218-1224, 2008.
 
6) Nakamura H, Arakawa K, Itakura H, et al : Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study) : a prospective randomised controlled trial. Lancet 368 : 1155-1163, 2006.
PubMed
7) Itoh H, Komuro I, Takeuchi M, et al : Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy : Report of a Randomized Study. Diabetes Care 41 : 1275-1284, 2018.
PubMed
8) Itoh H, Komuro I, Takeuchi M, et al : Achieving LDL cholesterol target levels < 1.81 mmol/L may provide extra cardiovascular protection in patients at high risk : Exploratory analysis of the Standard Versus Intensive Statin Therapy for Patients with Hypercholesterolaemia and Diabetic Retinopathy study. Diabetes Obes Metab 21 : 791-800, 2019.
PubMed
9) Ouchi Y, Sasaki J, Arai H, et al : Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75) : A Randomized, Controlled Trial. Circulation 140 : 992-1003, 2019.
PubMed
10) Okazaki S, Yokoyama T, Miyauchi K, et al : Early statin treatment in patients with acute coronary syndrome : demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event : the ESTABLISH Study. Circulation 110 : 1061-1068, 2004.
PubMed
11) Hiro T, Kimura T, Morimoto T, et al : Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome : a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 54 : 293-302, 2009.
 
12) Takayama T, Hiro T, Yamagishi M, et al : Effect of rosuvastatin on coronary atheroma in stable coronary artery disease : multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ J 73 : 2110-2117, 2009.
PubMed
13) Nakajima N, Miyauchi K, Yokoyama T, et al : Effect of combination of ezetimibe and a statin on coronary plaque regression in patients with acute coronary syndrome : ZEUS trial (eZEtimibe Ultrasound Study). IJC Metabolic & Endocrine 3 : 8-13, 2014.
 
14) Tsujita K, Sugiyama S, Sumida H, et al : Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention : The Multicenter Randomized Controlled PRECISE-IVUS Trial. J Am Coll Cardiol 66 : 495-507, 2015.
 
15) Nicholls SJ, Hsu A, Wolski K, et al. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol 55 : 2399-2407, 2010.
PubMed
16) Taguchi I, Iimuro S, Iwata H, et al : High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD) : A Randomized Superiority Trial. Circulation 137 : 1997-2009, 2018.
PubMed
17) Hagiwara N, Kawada-Watanabe E, Koyanagi R, et al : Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia : the HIJ-PROPER study, a prospective, open-label, randomized trial. Eur Heart J 38 : 2264-2276, 2017.
PubMed
18) Amarenco P, Labreuche J : Lipid management in the prevention of stroke : review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 8 : 453-463, 2009.
PubMed
19) McKinney JS, Kostis WJ : Statin therapy and the risk of intracerebral hemorrhage : a meta-analysis of 31 randomized controlled trials. Stroke 43 : 2149-2156, 2012.
PubMed
20) Salvatore T, Morganti R, Marchioli R, et al : Cholesterol Lowering and Stroke : No Longer Room for Pleiotropic Effects of Statins-Confirmation from PCSK9 Inhibitor Studies. Am J Med 133 : 95-99.e6, 2020.
 
21) Pandit AK, Kumar P, Kumar A, et al : High-dose statin therapy and risk of intracerebral hemorrhage : a meta-analysis. Acta Neurol Scand 134 : 22-28, 2016.
 
22) Judge C, Ruttledge S, Costello M, et al : Lipid Lowering Therapy, Low-Density Lipoprotein Level and Risk of Intracerebral Hemorrhage-A Meta-Analysis. J Stroke Cerebrovasc Dis 28 : 1703-1709, 2019.
PubMed
23) Cheng Y, Qiao L, Jiang Z, et al : Significant reduction in the LDL cholesterol increases the risk of intracerebral hemorrhage : a systematic review and meta-analysis of 33 randomized controlled trials. Am J Transl Res 12 : 463-477, 2020.
PubMed
24) Hulten E, Jackson JL, Douglas K, et al : The effect of early, intensive statin therapy on acute coronary syndrome : a meta-analysis of randomized controlled trials. Arch Intern Med 166 : 1814-1821, 2006.
 
25) Soran H, Kwok S, Adam S, et al : Evidence for more intensive cholesterol lowering. Curr Opin Lipidol 28 : 291-299, 2017.
PubMed
26) Natsuaki M, Furukawa Y, Morimoto T, et al : Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization. Perspectives from the CREDO-Kyoto registry cohort-2. Circ J 76 : 1369-1379, 2012.
PubMed
27) Nakamura M, Ako J, Arai H, et al : Lipid Management and 2-Year Clinical Outcomes in Japanese Patients with Acute Coronary Syndrome : EXPLORE-J. J Atheroscler Thromb 28 : 1307-1322, 2021.
 
28) Silverman MG, Ference BA, Im K, et al : Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions : A Systematic Review and Meta-analysis. JAMA 316 : 1289-1297, 2016.
 
29) Puymirat E, Bonaca M, Fumery M, et al : Atherothrombotic risk stratification after acute myocardial infarction : The Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention in the light of the French Registry of Acute ST Elevation or non-ST Elevation Myocardial Infarction registries. Clin Cardiol 42 : 227-234, 2019.
PubMed
30) Bohula EA, Morrow DA, Giugliano RP, et al : Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. J Am Coll Cardiol 69 : 911-921, 2017.
PubMed
31) Ni YG, Condra JH, Orsatti L, et al : A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake. J Biol Chem 285 : 12882-12891, 2010.
PubMed
32) Kiyosue A, Honarpour N, Kurtz C, et al : A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk. Am J Cardiol 117 : 40-47, 2016.
 
33) Teramoto T, Kobayashi M, Tasaki H, et al : Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins-ODYSSEY JAPAN Randomized Controlled Trial. Circ J 80 : 1980-1987, 2016.
 
34) Bhatt DL, Steg PG, Miller M, et al : Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 380 : 11-22, 2019.
PubMed
35) Saito Y, Yokoyama M, Origasa H, et al : Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors : sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 200 : 135-140, 2008.
PubMed
36) Nicholls SJ, Lincoff AM, Garcia M, et al : Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk : The STRENGTH Randomized Clinical Trial. JAMA 324 : 2268-2280, 2020.
PubMed
37) Keech A, Simes RJ, Barter P, et al : Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study) : randomised controlled trial. Lancet 366 : 1849-1861, 2005.
 
38) Ginsberg HN, Elam MB, Lovato LC, et al : Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362 : 1563-1574, 2010.
PubMed
39) Scott R, O'Brien R, Fulcher G, et al : Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome : the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 32 : 493-498, 2009.
 
40) Elam MB, Ginsberg HN, Lovato LC, et al ; ACCORDION Study Investigators : Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol 2 : 370-380, 2017
 
41) Jakob T, Nordmann AJ, Schandelmaier S, et al : Fibrates for primary prevention of cardiovascular disease events. Cochrane Database Syst Rev 11 : Cd009753, 2016.
PubMed
42) Wang D, Liu B, Tao W, et al : Fibrates for secondary prevention of cardiovascular disease and stroke. Cochrane Database Syst Rev 2015 : Cd009580, 2015.
 
43) Maki KC, Guyton JR, Orringer CE, et al : Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia. J Clin Lipidol 10 : 905-914, 2016.
PubMed
44) Marston NA, Giugliano RP, Im K, et al : Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes : A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. Circulation 140 : 1308-1317, 2019.
PubMed
45) Sabatine MS, Giugliano RP, Keech AC, et al : Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 376 : 1713-1722, 2017.
PubMed
46) Schwartz GG, Steg PG, Szarek M, et al : Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med 379 : 2097-2107, 2018.
PubMed
47) Cannon CP, Blazing MA, Giugliano RP, et al : Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 372 : 2387-2397, 2015.
PubMed
48) Group ASC, Bowman L, Mafham M, et al : Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. N Engl J Med 379 : 1540-1550, 2018.
 
49) Investigators OT, Bosch J, Gerstein HC, et al : n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 367 : 309-318, 2012.
 
50) Pradhan AD, Paynter NP, Everett BM, et al : Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. Am Heart J 206 : 80-93, 2018.
PubMed
51) Tsimikas S, Moriarty PM, Stroes ES : Emerging RNA Therapeutics to Lower Blood Levels of Lp (a) : JACC Focus Seminar 2/4. J Am Coll Cardiol 77 : 1576-1589, 2021.
PubMed
52) 日本動脈硬化学会 編 : 動脈硬化性疾患予防ガイドライン 2022年版, 2022.
 
P.1291 掲載の参考文献
1) Mabuchi H : Half a Century Tales of Familial Hypercholesterolemia (FH) in Japan. J Atheroscler Thromb 24 (3) : 189 -207, 2017.
 
2) Beheshti SO, Madsen CM, Varbo A, et al : Worldwide Prevalence of Familial Hypercholesterolemia : Meta-Analyses of 11 Million Subjects. J Am Coll Cardiol 75 (20) : 2553-2566, 2020.
PubMed
3) Harada-Shiba M, Arai H, Ishigaki Y, et al : Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia 2017. J Atheroscler Thromb 25 (8) : 751 -770, 2018.
 
4) Harada-Shiba M, Ohta T, Ohtake A, et al : Guidance for Pediatric Familial Hypercholesterolemia 2017. J Atheroscler Thromb 25 (6) : 539 -553, 2018.
 
5) Mabuchi H, Ito S, Haba T, et al : Discrimination of familial hypercholesterolemia and secondary hypercholesterolemia by Achilles' tendon thickness. Atherosclerosis 28 (1) : 61 -68, 1977.
 
6) Tada H, Hori M, Matsuki K, et al : Achilles Tendon Thickness Assessed by X-ray Predicting a Pathogenic Mutation in Familial Hypercholesterolemia Gene. J Atheroscler Thromb 29 (6) : 816-824, 2022
 
7) Michikura M, Ogura M, Yamamoto M, et al : Achilles Tendon Ultrasonography for Diagnosis of Familial Hypercholesterolemia Among Japanese Subjects. Circ J 81 (12) : 1879-1885, 2017.
PubMed
8) Tada H, Okada H, Nohara A, et al : Genetic mutations, regression of Achilles tendon thickness, and cardiovascular events among patients with familial hypercholesterolemia. Atherosclerosis 340 : 28-34, 2021.
PubMed
9) Nomura A, Tada H, Okada H, et al : Impact of genetic testing on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia (GenTLe-FH) : a randomised waiting list controlled open-label study protocol. BMJ Open 8 : e023636, 2018.
 
10) Nomura A, Tada H, Okada H, et al : Impact of Genetic Testing on Low-density Lipoprotein Cholesterol in Patients with Familial Hypercholesterolemia : GenTLe-FH randomized waited-list controlled trial. BMJ Open 8 (12) : e023636, 2018.
PubMed
11) Tada H, Kawashiri MA, Nohara A, et al : Remnant-like particles and coronary artery disease in familial hypercholesterolemia. Clin Chim Acta 482 : 120-123, 2018.
PubMed
12) Tada H, Kawashiri MA, Okada H, et al : Assessment of coronary atherosclerosis in patients with familial hypercholesterolemia by coronary computed tomography angiography. Am J Cardiol 115 (6) : 724-729, 2015.
PubMed
13) Tada H, Kawashiri MA, Okada H, et al : Assessments of Carotid Artery Plaque Burden in Patients With Familial Hypercholesterolemia. Am J Cardiol 120 (11) : 1955-1960, 2017.
PubMed
14) Fahed AC, Wang M, Homburger J R, et al : Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions. Nat Commun 11 (1) : 3635, 2020.
PubMed
15) Tada H, Kawashiri MA, Nohara A, et al : Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia. Eur Heart J 38 (20) : 1573-1579, 2017.
PubMed
16) Tada H, Kawashiri MA, Nomura A, et al : Oligogenic familial hypercholesterolemia, LDL cholesterol, and coronary artery disease. J Clin Lipidol 12 (6) : 1436-1444, 2018.
PubMed
17) Raal FJ, Rosenson RS, Reeskamp LF, et al : Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med 383 (8) : 711-720, 2020.
PubMed
18) Tada H, Okada H, Nomura A, et al : Prognostic impact of cascade screening for familial hypercholesterolemia on cardiovascular events. J Clin Lipidol 15 (2) : 358-365, 2021.
PubMed
19) Klancar G, Groselj U, Kovac J, et al : Universal Screening for Familial Hypercholesterolemia in Children. J Am Coll Cardiol 66 (11) : 1250-1257, 2015.
 
20) Matsunaga K, Mizobuchi A, Fu HY, et al : Universal Screening for Familial Hypercholesterolemia in Children in Kagawa, Japan. J Atheroscler Thromb 29 (6) : 839-849, 2022
 
21) Fahed AC, Wang M, Patel AP, et al : Association of the Interaction Between Familial Hypercholesterolemia Variants and Adherence to a Healthy Lifestyle With Risk of Coronary Artery Disease. JAMA Netw Open 5 (3) : e222687, 2022
PubMed
P.1298 掲載の参考文献
1) Kim K, Ginsberg HN, Choi SH : New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk : Beyond Statins. Diabetes Metab J 46 : 517-532, 2022.
PubMed
2) Abifadel M, Varret M, Rabes JP, et al : Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34 : 154-156, 2003.
PubMed
3) Benjannet S, Hamelin J, Chretien M, et al : Lossand gain-of-function PCSK9 variants : cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation. J Biol Chem 287 : 33745-33755, 2012.
 
4) Do RQ, Vogel RA, Schwartz GG : PCSK9 Inhibitors : potential in cardiovascular therapeutics. Curr Cardiol Rep 15 : 345, 2013.
PubMed
5) Robinson JG, Farnier M, Krempf M, et al : Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372 : 1489-1499, 2015.
PubMed
6) Sabatine MS, Giugliano RP, Wiviott SD, et al : Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372 : 1500-1509, 2015.
PubMed
7) Ray KK, Landmesser U, Leiter LA, et al : Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. N Engl J Med 376 : 1430-1440, 2017.
PubMed
8) Hovingh GK, Lepor NE, Kallend D, et al : Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia : The ORION-2 Pilot Study. Circulation 141 : 1829-1831, 2020.
PubMed
9) Henney NC, Banach M, Penson PE : RNA Silencing in the Management of Dyslipidemias. Curr Atheroscler Rep 23 : 69, 2021.
PubMed
10) Yamamoto T, Harada-Shiba M, Nakatani M, et al : Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice. Mol Ther Nucleic Acids 1 : e22, 2012.
PubMed
11) Wada F, Yamamoto T, Kobayashi T, et al : Drug discovery and development scheme for liver-targeting bridged nucleic acid antisense oligonucleotides. Mol Ther Nucleic Acids 26 : 957-969, 2021.
PubMed
12) Dewey FE, Gusarova V, Dunbar RL, et al : Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. N Engl J Med 377 : 211-221, 2017.
PubMed
13) Harada-Shiba M, Ali S, Gipe DA, et al : A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects. Atherosclerosis 314 : 33-40, 2020
PubMed
14) Raal FJ, Rosenson RS, Reeskamp LF, et al : Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med 383 : 711-720, 2020.
PubMed
15) Graham MJ, Lee RG, Brandt TA, et al : Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides. N Engl J Med 377 : 222-232, 2017.
PubMed
16) Viney NJ, van Capelleveen JC, Geary RS, et al : Antisense oligonucleotides targeting apolipoprotein (a) in people with raised lipoprotein (a) : two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 388 : 2239-2253, 2016.
PubMed
17) Koren MJ, Moriarty PM, Baum SJ, et al : Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein (a). Nat Med 28 : 96-103, 2022.
PubMed

【臨床試験】

P.1318 掲載の参考文献
1) サムスカOD錠7.5mg, サムスカOD錠15mg, サムスカOD錠30mg, サムスカ顆粒1%の医薬品インタビューフォーム (2021年7月改訂〔第22版〕) (大塚製薬株式会社).
 
2) サムスカOD錠7.5mg, サムスカOD錠15mg, サムスカOD錠30mg, サムスカ顆粒1%の医薬品添付文書 (2021年6月改訂〔第3版〕) (大塚製薬株式会社).
 
3) 後発医薬品の生物学的同等性試験ガイドライン (平成9年12月22日医薬審 第487号〔平成13年5月31日医薬審発 第786号, 平成18年11月24日 薬食審査発 第1124004号, 平成24年2月29 日薬食審査発0229 第10号にて一部改正〕).
 
4) 「後発医薬品の生物学的同等性試験ガイドライン等の改正 (案) 」に関する御意見の募集について (平成31年2月28日医薬品審査管理課).
 
5) 奥田豊 : RACTAB(R) 技術を活用したOD錠の製剤設計. 薬剤学 71 (1) : 21, 2011.
Medical*Online
6) 医薬品の臨床試験の実施の基準に関する省令 (平成9年3月27日厚生省令第28号〔平成15年6月12日厚生労働省令第106号, 平成16年12月21日厚生労働省令第172号, 平成18年3月31日厚生労働省令第72号, 平成20年2月29日厚生労働省令第24号, 平成24年12月28日厚生労働省令第161号, 平成28年1月22日厚生労働省令第9号にて一部改正〕).
 
P.1335 掲載の参考文献
1) レクサプロ錠10mg, レクサプロ錠20mgの医薬品添付文書 (2018年11月改訂〔第8版〕) (持田製薬株式会社).
 
2) 後発医薬品の生物学的同等性試験ガイドライン (平成9年12月22日医薬審第487号 (平成13年5月31日医薬審発第786号, 平成18年11月24日 薬食審査発第1124004号, 平成24年2月29日 薬食審査発0229 第10号にて一部改正).
 
3) 奥田豊 : RACTAB(R) 技術を活用したOD錠の製剤設計. 薬剤学 71 (1) : 21, 2011.
Medical*Online
4) 医薬品の臨床試験の実施の基準に関する省令 (平成9年3月27日厚生省令第28号), 医薬品の臨床試験の実施の基準に関する省令の一部を改正する省令 (平成15年6月12日厚生労働省令第106号, 平成16年12月21日厚生労働省令第172号, 平成18年3月31日厚生労働省令第72号, 平成20年2月29日厚生労働省令第24号, 平成28年1月22日厚生労働省令第9号), 薬事法施行規則等の一部を改正する省令 (平成24年12月28日厚生労働省令第161号).
 

【薬理・薬剤】

P.1349 掲載の参考文献
1) 医薬品インタビューフォーム レクサプロ(R) 錠10mg, レクサプロ(R) 錠20mg. 2021年1月改訂 (第11版)
 
2) 安定性試験実施方法のガイドライン (平成3年2月15日薬審第43号)
 
3) 錠剤・カプセル剤の無包装状態での安定性情報 (改訂5版, 医薬ジャーナル社)
 
4) 第十八改正日本薬局方 (令和3年6月7日厚生労働省告示第220号)
 
5) 後発医薬品の生物学的同等性試験ガイドライン (平成9年12月22日付け医薬審第487号一部改正令和2年3月19日付薬生薬審発0319 第1号)
 
6) 含量が異なる経口固形製剤の生物学的同等性試験ガイドライン (平成12年2月14日医薬審第64号 一部改正令和2年3月19日薬生薬審発0319 第1号)
 
P.1358 掲載の参考文献
1) 厚生労働省・経済産業省・消費者庁 新型コロナウイルスの消毒・除菌方法について https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/syoudoku_00001.html [参照2022年8月26日]
 
2) Nomura T, Nazmul T, Sakaguchi T, et al : Ethanol susceptibility of SARS-CoV-2 and other enveloped viruses. Biocont Sci 26 (3) : 177-180, 2021.
 
3) 日本感染症学会 ノロウイルス感染症 https://www.kansensho.or.jp/ref/d50.html [参照2022年8月26日]
 
4) Ueda K, Kawabata R, Sakaguchi T, et al : Inactivation of pathogenic viruses by plant-derived tannins : strong effects of extracts from persimmon (Diospyros kaki) on a board range of viruses. PLoS One 8 (1) : e55343, 2013.
 
5) Noma K, Kiyotani K, Kouchi H, et al : Endogenous protease-dependent replication of human influenza viruses in two MDCK cell lines. Arch Virol 143 (10) : 1893-1909, 1998.
PubMed
6) Coyne CB, Oberste MS, Pallansh MA : Enteroviruses : Polioviruses, Coxsackieviruses, Echoviruses, and Newer Enteroviruses. Fields Virology 7th, vol 1 (ed. by Howley PM, Knipe DM), p.87, Wolters Kluwer, Philadelphia 2021.
 
7) Ohmine T, Narai S, Sakaguchi T, et al : Eligibility of feline calicivirus for a surrogate of human norovirus in comparison with murine norovirus, poliovirus and coxsackievirus. Biocont Sci 23 (3) : 145-149, 2018.
 
8) イギリス保健省Emerging infections : how and why they arise. https://www.gov.uk/government/publications/emerging-infections-characteristics-epidemiology-and-global-distribution/emerging-infections-howand-why-they-arise [参照2022年8月26日]
 

【研究】

P.1366 掲載の参考文献
1) 川上裕子, 川上敏明 : マスト細胞活性化とアレルギー疾患. 生化学 92 (4) : 517-526, 2020.
 
2) 中島裕史 : 喘息モデルマウス. アレルギー 59 (11) : 1539-1545, 2010.
Medical*Online
3) 萩野敏, 榎本雅夫, 和田光雄 : アレルギー性鼻炎と住環境ダニ抗原量. 耳鼻臨床 95 (1) : 45-50, 2002.
 
4) Kato G, Takahashi K, Tashiro H, et al : β2 adrenergic agonist attenuates house dust mite-induced allergic airway inflammation through dendritic cells. BMC Immunology 15 : 39, 2014.
 
5) Tashiro H, Takahashi K, Hayashi S, et al : Interleukin-33 from Monocytes Recruited to the Lung Contributes to House Dust Mite-Induced Airway Inflammation in a Mouse Model. PLoS One 11 (6) : 2016.
 
6) Tashiro H, Takahashi K, Sadamatsu H, et al : Saturated Fatty Acid Increases Lung Macrophages and Augments House Dust Mite-Induced Airway Inflammation in Mice Fed with High-Fat Diet. Inflammation 40 (3) : 1072-1086, 2017.
PubMed
7) Ishii T, Niikura Y, Kurata K, et al : Time-dependent distinct roles of Toll-like receptor 4 in a house dust mite-induced asthma mouse model. Scand J Immunology 87 (3) : e12641, 2018.
 
8) 稲垣直樹 : 最近のアレルギー研究の進歩. 日薬理誌 131 : 22-27, 2008.
Medical*Online
9) 井上博雅 : II. 病因と病態 2. 気道炎症と気道リモデリングの分子病態. 日本内科学会雑誌 98 (12) : 3006-3012, 2009.
 
10) 斎藤博久 : 特集I マスト細胞を軸としたアレルギー・感染・炎症 気道リモデリングとマスト細胞. 炎症と免疫 14 (5) : 586-591, 2006.
 
11) 斎藤博久 : 医学と医療の最前線 マイクロアレイ法による新しいアレルギー炎症性疾患診断マーカー. 日本内科学会雑誌 96 (6) : 140-145, 2007.
 
12) 斎藤博久 : 喘息における組織リモデリング : マスト細胞の役割を中心に. 日薬理誌 134 : 64-67, 2009.
Medical*Online
P.1376 掲載の参考文献
1) Hatakeyama T, Matsuda K, Osawa M, Sagehashi N, Kumagai M : Change in cleanliness over time following introduction of microfiber cloth for wipe cleaning of medical instruments. J Jpn Assoc Clin Engineer Technologists 56 : 100-103, 2016. (In Japanese)
 
2) Hatakeyama T, Matsuda K, Osawa M, Sagehashi N, Kumagai M : Study on usefulness of Toraysee(R) for CE. J Jpn Assoc Clin Engineer Technologists 53 : 67-71, 2015. (In Japanese)
 
3) Nakamura K, Tojo K, Sato E, Kunimi M, et al : An investigation of cleaning cloths. The Japanese Journal of Medical Instrumentation 82 (2) : 600-601, 2012. (In Japanese)
 
4) Matsumoto Y, Takahashi K, and Urano H. Removal of bacterial cells adhering to surface by using a wiping cloth. J Antibact Antifung Agents 43 : 3-7, 2015. (In Japanese)
 
5) Muto M, et al : Investigation of disinfecting effect of wiping with a cleaning cloth (Toraysee for CE). J Jpn Assoc Clin Engineer Technologists 51-262, 2014. (In Japanese)
 
6) Tojo K, Nakamura K, Sato E, Hayami S, Fujii M, Miyaji K : Effectiveness of microfiber cleaning cloth used for medical equipment. Ther Res 34 : 399-407, 2013. (In Japanese)
 
7) National Institute of Technology and Evaluation. Investigative committee on efficacy assessment on alternative disinfection methods for the SARSCoV-2 virus, Efficacy assessment on alternative disinfection methods for the SARS-CoV-2 virus (Final Report), 2020 June. (In Japanese) https://www.nite.go.jp/data/000111315.pdf [Accessed 8 Aug 2021]
 
8) Satoshi Fukuzaki : Features and medical applications of microfiber cloth for cleaning equipment. Journal of Antibacterial and Antifungal Agents. ISSN 2187-431X. (In Japanese)
 
9) Satoshi Fukuzaki : Features and Medical Applications of Microfiber Cloth for Cleaning Instruments with Wipes. Ther Res 40 (11) : 2019.
Medical*Online
10) Amauchi M, Soman K, Hirata A, Fushimi R, Okamoto N, Takahashi R, et al : Study of wiping, transferring and oozing of three kinds of wipes (materials) by evaluating ATP. J Healthcare-assoc Infect 9 : 42-51, 2016. (In Japanese)
 
11) Tojo K, Nojima Y, Sagehashi N, Nakamura K, Sato M, Fujii M, et al. Evaluation of virus removal efficiency with a microfiber cleaning cloth. Ther Res 35 : 827-836, 2014. (In Japanese)
 
12) Tojo K, Fujii M, Nakamura K, Sato M, Nojima Y, Sagehashi N, Evaluation of virus removal efficiency with a microfiber cleaning cloth. Jpn J Med Instrument 87 : 40-46, 2017. (In Japanese)
 
13) Japan Ministry of Health, Labour and Welfare. Special Web Page of Ministry of Health, Labour and Welfare/Ministry of Economy, Trade and Industry/Consumer Affairs Agency : On disinfection/elimination methods for the SARS-CoV-2 virus. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/syoudoku_00001.html [Accessed 1 May 2022]
 
14) Japan Hygiene Products Industry Association. Methodology for testing the disinfection performance of wet wipes (enacted on April 1, 2013)
 
15) Sato M, Tojo K, Nakamura K, Kunimi M, et al : Investigation into wiping up blood with Toraysee microfiber material cleaning cloth. J Jpn Assoc Clin Engineer Technologists 51 : 254, 2014.
 
16) CDC Sterilization in Healthcare Facilities, Nov. 2018
PubMed

【Diagnosis】

P.1385 掲載の参考文献
1) World Health Organisation : Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update. https://www.who.int/publications/m/item/weeklyepidemiological-update-on-covid-19 [accessed 19 August 2022]
 
2) 厚生労働省 健康局 結核感染症課 : 新型コロナウイルス感染症の現在の状況と厚生労働省の対応について (令和4年7月15日版) https://www.mhlw.go.jp/stf/newpage_26818.html
 
3) 厚生労働省 病原体検査の指針検討委員会 : 新型コロナウイルス感染症 (COVID-19) 病原体検査の指針 (第5.1版. 2022年3月17日)
 
4) 廣津伸夫, 菊地直子, 深谷千佳, 他 : 銀増幅イムノクロマトグラフィーを用いた高感度SARS-CoV-2抗原検出システムの臨床評価. 医学と薬学 78 (7) : 873-879, 2021.
Medical*Online
5) 国立感染症研究所 : 病原体検出マニュアル 2019-nCoV (Ver.2.9.1, 2020年3月19日)
 
6) Joseph Ojonugwa Shaibu, Chika K Onwuamah, Ayorinde Babatunde James, et al : Full length genomic sanger sequencing and phylogenetic analysis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Nigeria. PloS one 16 (1) : 2021. e0243271. doi : 10.1371/journal.pone.0243271.
 
7) World Health Organisation : Target product profiles for priority diagnostics to support response to the COVID-19 pandemic v.1.0 2020 September.
 
8) Min-Chul Kim, Chunguang Cui, Kyeong-Ryeol Shin, et al : Duration of Culturable SARS-CoV-2 in Hospitalized Patients with Covid-19. The New England journal of medicine 18 : 384 (7) : 671-673, 2021. doi : 10.1056/NEJMc2027040.
 
9) Dalia Raich-Regue, Jordana Munoz-Basagoiti, Daniel Perez-Zsolt, et al : Performance of SARSCoV-2 Antigen-Detecting Rapid Diagnostic Tests for Omicron and Other Variants of Concern. Frontiers in microbiology 13 : 810576, 2022. doi : 10.3389/fmicb.2022.810576.
 
10) Justin Hardick, Nicholas Gallagher, Jaiprasath Sachithanandham, et al : Evaluation of Four Point of Care (POC) Antigen Assays for the Detection of the SARS-CoV-2 Variant Omicron. Microbiology spectrum 10 (3) : e0102522, 2022. doi : 10.1128/spectrum.01025-22.
 
P.1395 掲載の参考文献
1) Qun Li, et al : Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med 382 : 1199-207, 2020.
PubMed
2) 厚生労働省 診療の手引き検討委員会 : 新型コロナウイルス感染症 (COVID-19) 診療の手引き (第7.2版, 2022年5月9日)
 
3) David M Morens, Jeffery K Taubenberger, Anthony S Faucil : Predominant role of bacterial pneumonia as a cause of death in pandemic influenza : implications for pandemic influenza preparedness. J Infect Dis 198 : 962-970, 2008.
 
4) Bradley J Langford, Miranda So, Sumit Raybardhan, et al : Bacterial co-infection and secondary infection in patients with COVID-19 : a living rapid review and meta-analysis. Clin Microbiol Infect 26 : 1622-1629, 2020.
PubMed
5) Pontus Hedberg, Niclas Johansson, Anders Ternhag, et al : Bacterial co-infections in community-acquired pneumonia caused by SARS-CoV-2, influenza virus and respiratory syncytial virus. BMC Infect Dis 22 : 108, 2022.
PubMed
6) Anahita Rouze, Ignacio Martin-Loeches, Pedro Povoa, et al : Early Bacterial Identification among Intubated Patients with COVID-19 or Influenza Pneumonia : A European Multicenter Comparative Clinical Trial. Am J Respir Crit Care Med 204 : 546-556, 2021.
PubMed
7) Tetsuya Tsukamoto, Noriko Nakajima, Aki Sakurai, et al : Lung Pathology of Mutually Exclusive Co-infection with SARS-CoV-2 and Streptococcus pneumoniae. Emerg Infect Dis 27 : 919-923, 2021.
PubMed
8) 日本呼吸器学会 : 成人肺炎診療ガイドライン 2017
 
P.1406 掲載の参考文献
1) メソトレキセート点滴静注液200mg/1000 mg 添付文書.
 
2) Treon SP, Chabner BA : Concepts in use of highdose methotrexate therapy. Clinical chemistry 42 : 1322-1329, 1996.
PubMed
3) Howard SC, McCormick J, Ching-Hon Pui, et al : Preventing and managing toxicities of high-dose methotrexate. The oncologist 21 : 1471-1482, 2016.
PubMed
4) Nishizono I, Iida S, N Suzuki N, et al : Rapid and Sensitive Chemiluminescent Enzyme Immunoassay for Measuring Tumor Markers. Clin Chem 37 : 1639-1644, 1991.
 
5) Clinical and Laboratory Standards Institute. Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures ; Approved Guideline-Second Edition. CLSI Document EP17-A2.
 
6) 中村裕美, 名執由起, 小林葉子, 他 : メトトレキサートの測定試薬2法の性能評価. 医学検査 65 (3) : 290-297, 2016.
 
7) ルミパルスプレスト メトトレキサート 添付文書.
 
8) ナノピアeTDMメトトレキサート 添付文書.
 

【Cosmetic】

P.1418 掲載の参考文献
1) 高橋康之 : 2. 健やかな肌をつくるための保湿化粧品. 日本皮膚科学会雑誌 132 (6) : 1449-1455, 2022.
 
2) 前田憲寿 : 皮膚と化学-内と外の境界-. 化学と教育 65 (2) : 84-85, 2017.
 
3) 酒井裕二 : 理想的な洗顔料の開発. 日本化粧品技術者会誌 33 (2) : 109-118, 1999.
 
4) 南野美紀 : 化粧品の種類と使い方-スキンケア化粧品-. 日本香粧品学会誌 42 (2) 109-124. 2018.
 
5) 抗老化機能評価専門委員会 : 新規効能取得のための抗シワ製品評価ガイドライン. 日本香粧品学会誌 30 (4) : 316-332, 2006.
 
6) 柳井久江 : 4 Steps エクセル統計 第4版. オーエムエス出版, 東京, 2015.
 
7) 正木仁 : 機能性化粧品の展望. 薬剤学 75 (5) : 313-316, 2015.
Medical*Online
8) 酒井裕二, 鈴木将史 : 高極性油エマルションの性質と化粧品への活用について. オレオサイエンス 4 (3) : 91-96, 2004.
 
9) 藤原信太郎, 牛木勝 : キメの形態と頬部のけ穴目立ちとの関連性. 日本香粧学会誌 39 (3) : 173-176, 2015.
 
10) 西島貴史 : 頬の表皮構造による毛穴目立ちとその改善へのアプローチ. 日本化粧品技術者会誌 43 (1) : 3-9, 2009.
 
11) 小西奈津子 : 女性外来 (スキンケア専門) での毛穴治療. 日本化粧品技術者会誌 42 (8) : 89-93, 2008.
 
12) 山田秀和 : 最近の女性に多いシワの種類に対する傾向と対策. COSMETIC CTAGE 12 (2) : 1-7, 2017.
 
13) 山崎律子 : 加齢による皮膚の変化とスキンケア. 繊維製品消費科学 55 (11) : 823-826, 2014.
 

書評

最近チェックした商品履歴

Loading...